BCTXL

BriaCell Therapeutics Warrant

BCTXL

1.07 USD

+0.10

10.3%

At close Updated Mar 12, 4:00 PM EDT

Pre-market

After hours

1.08

+0.01

0.93%

1 day

10.3%

5 days

1.9%

1 month

12.63%

3 months

15.05%

6 months

15.05%

Year to date

15.05%

1 year

15.05%

5 years

15.05%

10 years

15.05%

About: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Employees: 4

Healthcare Drug Manufacturers - General

–

Funds holding %

of 8,072 funds

Explore Fund Trends

–

Analysts bullish %

See Analyst Outlook

–

Positive news %

Check Journalist POV